Exelixis
EXEL
#1695
Rank
ยฃ7.89 B
Marketcap
ยฃ27.64
Share price
0.52%
Change (1 day)
65.18%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total liabilities

Total liabilities on the balance sheet as of September 2024 : ยฃ0.54 Billion

According to Exelixis's latest financial reports the company's total liabilities are ยฃ0.54 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Exelixis - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31ยฃ0.53 B10.5%
2022-12-31ยฃ0.48 B60.38%
2021-12-31ยฃ0.30 B58.62%
2020-12-31ยฃ0.18 B24.39%
2019-12-31ยฃ0.15 B43.37%
2018-12-31ยฃ0.10 B-61.24%
2017-12-31ยฃ0.27 B-33.24%
2016-12-31ยฃ0.41 B28.55%
2015-12-31ยฃ0.31 B13.47%
2014-12-31ยฃ0.28 B6.2%
2013-12-31ยฃ0.26 B0.84%
2012-12-31ยฃ0.26 B34.94%
2011-12-31ยฃ0.19 B-48.98%
2010-12-31ยฃ0.38 B21.77%
2009-12-31ยฃ0.31 B0.31%
2008-12-31ยฃ0.31 B90.03%
2007-12-31ยฃ0.16 B5.65%
2006-12-31ยฃ0.15 B-2.57%
2005-12-31ยฃ0.15 B27.4%
2004-12-31ยฃ0.12 B14.23%
2003-12-31ยฃ0.10 B7.83%
2002-12-31ยฃ0.10 B34.9%
2001-12-31ยฃ75.44 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
ยฃ47.35 B 8,614.84%๐Ÿ‡ฌ๐Ÿ‡ง UK
ยฃ48.27 B 8,784.15%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ57.90 B 10,555.07%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ60.67 B 11,065.83%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ66.14 B 12,071.30%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ85.79 B 15,688.55%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ100.70 B 18,432.04%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ40.55 M-92.54%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ57.43 M-89.43%๐Ÿ‡บ๐Ÿ‡ธ USA